Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, singl...

por Hibi, Toshifumi, Hirohata, Shunsei, Kikuchi, Hirotoshi, Tateishi, Ukihide, Sato, Noriko, Ozaki, Kunihiko, Kondo, Kazuoki, Ishigatsubo, Yoshiaki
Publicado 2016

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial an...

por Kobayashi, Taku, Suzuki, Yasuo, Motoya, Satoshi, Hirai, Fumihito, Ogata, Haruhiko, Ito, Hiroaki, Sato, Noriko, Ozaki, Kunihiko, Watanabe, Mamoru, Hibi, Toshifumi
Publicado 2015

Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan

por Tajiri, Hitoshi, Motoya, Satoshi, Kinjo, Fukunori, Maemoto, Atsuo, Matsumoto, Takayuki, Sato, Noriko, Yamada, Hiroshi, Nagano, Mieko, Susuta, Yutaka, Ozaki, Kunihiko, Kondo, Kazuoki, Hibi, Toshifumi
Publicado 2018

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan

por Tajiri, Hitoshi, Arai, Katsuhiro, Kagimoto, Seiichi, Kunisaki, Reiko, Hida, Nobuyuki, Sato, Noriko, Yamada, Hiroshi, Nagano, Mieko, Susuta, Yutaka, Ozaki, Kunihiko, Kondo, Kazuoki, Hibi, Toshifumi
Publicado 2019

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan

por Tajiri, Hitoshi, Motoya, Satoshi, Kinjo, Fukunori, Maemoto, Atsuo, Matsumoto, Takayuki, Sato, Noriko, Yamada, Hiroshi, Nagano, Mieko, Susuta, Yutaka, Ozaki, Kunihiko, Kondo, Kazuoki, Hibi, Toshifumi
Publicado 2022